Figures & data
Figure 1 Interaction of ligand with RET and cell-signaling pathways.
![Figure 1 Interaction of ligand with RET and cell-signaling pathways.](/cms/asset/f28b61b4-5007-4b81-a643-15e3d6a6d7a0/dbtt_a_24220_f0001_b.jpg)
Figure 2 VEGFR pathways within the tumor cell.
![Figure 2 VEGFR pathways within the tumor cell.](/cms/asset/5f20a270-29dc-44a9-92af-8e6ac282b794/dbtt_a_24220_f0002_b.jpg)
Table 1 Major adverse events reported in 20% or more patients on vandetanib 300 mg/day versus placebo in MTC
Register now or learn more
Open access
Figure 1 Interaction of ligand with RET and cell-signaling pathways.
Figure 2 VEGFR pathways within the tumor cell.
Table 1 Major adverse events reported in 20% or more patients on vandetanib 300 mg/day versus placebo in MTC
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.